Childhood epilepsy in Cameroon: Clinical patterns, predictive factors, and educational impact at a tertiary hospital

Dominique Enyama1, Daniel Gams Massi2, Diomede Noukeu Njinkui1

  • 1Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon; Pediatric Department, Douala Gyneco-Obstetric and Pediatric Hospital, Douala, Cameroon.

Brain & Development
|November 16, 2025
PubMed

Insights

Childhood epilepsy in Cameroon shows a 2.4% prevalence, with generalized seizures being most common. Poor seizure control is linked to unknown seizure types, focal epilepsy, and traditional medicine use.

Area of Science:

  • Neurology
  • Pediatrics
  • Epidemiology

Background:

  • Epilepsy is a chronic neurological disorder characterized by recurrent seizures.
  • Limited data exists on childhood epilepsy in Cameroon, necessitating this study.

Purpose of the Study:

  • To determine the prevalence and characteristics of childhood epilepsy in Cameroon.
  • To identify etiological factors, treatment patterns, and predictors of poor seizure control.
  • To assess the impact of epilepsy on cognitive function and school performance.

Main Methods:

  • A cross-sectional study with retrospective data collection was conducted over six months.
  • Medical records of 142 children (3 months to 15 years) diagnosed with epilepsy at Douala General Hospital (2020-2023) were analyzed.
  • Statistical analyses included Fisher's exact, chi-square tests, and logistic regression (p < 0.05).

Main Results:

  • Epilepsy prevalence was 2.4%, with generalized seizures in 65.7% and focal abnormalities in 50.7%.
  • Key etiological factors included neonatal convulsions (43%), febrile seizures (34.5%), and neonatal asphyxia (24.6%).
  • Poor seizure control was associated with unknown seizure type (OR 14.25), cryptogenic focal epilepsy (OR 12.55), and use of traditional medicine (OR 7.45). Memory disorders (OR 4.95) and lack of concentration (OR 3.04) impacted school performance.

Conclusions:

  • This study highlights significant etiological factors and predictors of poor seizure control in Cameroonian children with epilepsy.
  • Cognitive impairments, particularly memory disorders and lack of concentration, negatively affect school performance.
  • Findings provide targets for optimizing neurological and educational management strategies for childhood epilepsy in Cameroon.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
616
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
802
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K